Improving T cell therapy for cancer treatment
Reprogramming T cell function with multiplexed genome engineering to develop next-generation immunotherapy
This study is looking at ways to make T cell therapy better for cancer patients by improving how T cells are designed to find and attack cancer cells, which could help keep the cancer from coming back and lead to better results for patients.
Quick facts
| Grant type | Career grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Yale University NIH-funded |
| Lab location | 1 site (New Haven, United States) |
| Project ID | NIH-11052635 on NIH RePORTER |
What this research studies
This research focuses on enhancing the effectiveness of T cell therapy, specifically by engineering T cells with chimeric antigen receptors (CARs) to better target cancer cells. The approach involves using advanced techniques to modify the dynamics of these CARs, which are crucial for their function in attacking tumors. By investigating how to optimize these CAR designs, the research aims to reduce the chances of cancer relapse and improve patient outcomes. Patients may benefit from a more effective immunotherapy that can lead to longer-lasting responses against their cancer.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients with hematologic malignancies who are seeking advanced immunotherapy options.
Not a fit: Patients with solid tumors or those who do not have hematologic malignancies may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective T cell therapies that significantly improve cancer treatment outcomes.
How similar studies have performed: Previous research has shown promising results with CAR T cell therapies, indicating that optimizing CAR dynamics could lead to significant advancements in treatment efficacy.
Where this research is happening
New Haven, United States
- Yale University — New Haven, United States (Active)
Researchers
- Principal investigator: Zhou, Xiaoyu — Yale University
- Study coordinator: Zhou, Xiaoyu
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.